Andreas Konar - XSpray Pharma Sr Devel

All Insiders . Sweden . 
Stock . XSpray Pharma AB . Stakeholders . Insider . Andreas Konar
XSPRAY Stock  SEK 42.40  0.45  1.07%   

Insider

Andreas Konar is Sr Devel of XSpray Pharma AB
Age 74
Phone46 87 30 37 00
Webhttps://www.xspraypharma.com

XSpray Pharma Management Efficiency

The company has return on total asset (ROA) of (0.1448) % which means that it has lost $0.1448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2423) %, meaning that it generated substantial loss on money invested by shareholders. XSpray Pharma's management efficiency ratios could be used to measure how well XSpray Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
XSpray Pharma AB has accumulated 1.19 M in total debt with debt to equity ratio (D/E) of 2.8, implying the company greatly relies on financing operations through barrowing. XSpray Pharma AB has a current ratio of 25.92, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist XSpray Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, XSpray Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like XSpray Pharma AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for XSpray to invest in growth at high rates of return. When we think about XSpray Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

MSc MDOncopeptides AB
N/A
Stefan MBABioInvent International AB
60
MSc BAMoberg Pharma AB
43
Marie SvenssonAlligator Bioscience AB
59
Marie MobergMoberg Pharma AB
N/A
Bjrn FrendusBioInvent International AB
50
MSc MScOncopeptides AB
53
Malin CarlssonAlligator Bioscience AB
55
Mark BeveridgeMoberg Pharma AB
45
Pr MDOncopeptides AB
N/A
Anders BroijersenMoberg Pharma AB
N/A
Linda HolmstromOncopeptides AB
N/A
Jakob LicOncopeptides AB
51
Sylvie RyckebuschBioInvent International AB
N/A
Cecilia HofvanderBioInvent International AB
56
Gunilla WengstrmMoberg Pharma AB
N/A
Kerstin StrinnholmMoberg Pharma AB
63
Ingrid TeigeBioInvent International AB
N/A
Peter NygrenOncopeptides AB
64
RGN MScBioInvent International AB
N/A
Annika MBAOncopeptides AB
57
Xspray Pharma AB engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden. Xspray Pharma AB was founded in 2003 and is based in Solna, Sweden. Xspray Pharma is traded on Stockholm Stock Exchange in Sweden. XSpray Pharma AB (XSPRAY) is traded on Stockholm Exchange in Sweden and employs 26 people.

Management Performance

Return On Equity-0.24
Return On Asset-0.14

XSpray Pharma AB Leadership Team

Elected by the shareholders, the XSpray Pharma's board of directors comprises two types of representatives: XSpray Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XSpray. The board's role is to monitor XSpray Pharma's management team and ensure that shareholders' interests are well served. XSpray Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, XSpray Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kerstin Hasselgren, Chief Officer
Per Andersson, Chief Officer
Charlotta Liljebris, VP RD
Andreas Konar, Sr Devel
Thomas Walz, Chief Officer
AnnaKarin Ekberg, VP Sales
Christina Hagerstrand, VP Relations
Grald Jesson, VP Operations
Mustafa Demirbker, CoFounder Director

XSpray Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is XSpray Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.24
Return On Asset-0.14
Operating Margin(116.51) %
Current Valuation1.16 B
Shares Outstanding22.68 M
Shares Owned By Insiders47.42 %
Shares Owned By Institutions27.60 %
Price To Book2.35 X
Price To Sales1,206 X
Gross Profit656 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Other Information on Investing in XSpray Stock

XSpray Pharma financial ratios help investors to determine whether XSpray Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XSpray with respect to the benefits of owning XSpray Pharma security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY